Colin Lee Novick
Colin Lee Novick is cofounder and managing director of CJ PARTNERS. As an American born in South Korea and raised in Japan, Novick graduated from Japanese public school to study at Cornell University. After working as a management consultant at Deloitte Tohmatsu Consulting within the Financial Services Industry Group for three years, Novick sought out a new industry at SMBC Nikko Securities, where he facilitated mergers and acquisitions. In 2012, Novick and cross-cultural colleague Jason David Sieger founded CJ PARTNERS Inc. to assist in Japan Inc.'s development.
Recent Quotes
RP's Phase 1/2a trial for tendon repair in chronic Achilles tendinosis met its goal and established a complete safety profile at six months that showed no serious adverse events."
—
The Life Sciences Report Interview with Colin Lee Novick
(10/4/17)
more >
"The RGS-Asahi Glass deal is nicely designed."
—
The Life Sciences Report Interview with Colin Lee Novick
(2/1/17)
more >
"I would keep my eyes peeled on RP and Shiseido in the coming months for indications as to when the male pattern baldness therapy will become available in Japan."
—
The Life Sciences Report Interview with Colin Lee Novick
(2/1/17)
more >
"RGS is actively seeking Japanese partners for its adipose-derived mesenchymal stem cell osteoarthritis drug, Progenza."
—
The Life Sciences Report Interview with Colin Lee Novick
(8/5/15)
more >
"The RGS-Asahi Glass deal is nicely designed; RGS gets the upfront payments and the milestone payments from AGC, but it also gets a portion of subsequent milestone payments and upfront payments from any pharmaceutical company that it teams up with for the commercialization rights."
—
The Life Sciences Report Interview with Colin Lee Novick
(2/1/01)
more >
